Provided by Tiger Trade Technology Pte. Ltd.

Invesco Nasdaq Biotechnology ETF

34.69
-0.4365-1.24%
Post-market: 34.710.0207+0.06%19:30 EDT
Volume:25.49K
Turnover:885.29K
Market Cap:96.44M
PE:- -
High:35.13
Open:35.13
Low:34.63
Close:35.13
52wk High:36.84
52wk Low:23.42
Shares:2.78M
Float Shares:2.78M
Volume Ratio:1.14
T/O Rate:0.92%
Dividend:0.26
Dividend Rate:0.74%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Amgen's Olpasiran May Still Show Heart-Risk Reduction Despite Novartis Miss, UBS Says

MT Newswires Live
·
Sep 09

Gilead Opens State-of-the-Art Research Center to Advance the Next Generation of Medicines

THOMSON REUTERS
·
Sep 09

Royalty Pharma Falls After Novartis' Cholesterol Drug Fails in Study

Reuters
·
Sep 09

Amgen Pulls Dow Industrials Lower; Oil Jumps on Houthi Strikes in Saudi Arabia

Dow Jones
·
Sep 09

Top Midday Stories: GE Aerospace to Acquire Consolidated Precision Products; Qualcomm Issues Share Warrant to Amazon

MT Newswires Live
·
Sep 08

NASDAQ Top and Bottom Performing Stocks at About 11:01 A.m. EDT on 2026-09-08

Reuters
·
Sep 08

Amgen Says Phase 3 Study Meets Primary Endpoint in Small Cell Lung Cancer

MT Newswires Live
·
Sep 08

Amgen Inc Stock (AMGN) Moved Down by 8.33% on Sep 8: A Full Analysis

TradingKey
·
Sep 08

U.S. Stocks on the MOVE-Sigma Lithium, Shake Shack, Novartis

Reuters
·
Sep 08

AstraZeneca's COPD Candidate Shows Strong Results in Late-Stage Trials, Reviving a Once-Doubted Drug Target

Deep News
·
Sep 08

Dow Drops 438 Points on Losses for Amgen, Salesforce Shares

Dow Jones
·
Sep 08

Amgen Down Nearly 7%, on Pace for Largest Percent Decrease Since March 2020

Dow Jones
·
Sep 08

Amgen-AstraZeneca Cancer Drug Combo Hits Main Survival Goal in Late-Stage Trial

Reuters
·
Sep 08

AstraZeneca announces results from Phase III trial of IMFINZI, tarlatamab

TIPRANKS
·
Sep 08

Amgen - Phase 3 Dellphi-305 Study Delivers Significant Overall Survival Benefit Versus Durvalumab Alone

THOMSON REUTERS
·
Sep 08

Imdelltra® in Combination with Imfinzi® Demonstrated Landmark Improvement in Overall Survival in First-Line Extensive Stage Small Cell Lung Cancer

THOMSON REUTERS
·
Sep 08

Amgen - Study Meets Secondary Endpoints for Progression-Free Survival and Objective Response Rate

THOMSON REUTERS
·
Sep 08

Amgen - no New or Unexpected Safety Signals Identified in Dellphi-305 Study

THOMSON REUTERS
·
Sep 08

Chengdu Easton Biopharmaceuticals Schedules Participation in Semi-Annual Innovation Drug Sector Earnings Call

Deep News
·
Sep 08

Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Guardant Health (GH) and Neurocrine (NBIX)

TIPRANKS
·
Sep 08